Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 152741, 5 pages
http://dx.doi.org/10.1155/2015/152741
Research Article

Potential Use of Interleukin-10 Blockade as a Therapeutic Strategy in Human Cutaneous Leishmaniasis

1Laboratory of Immunology, Federal University of Triângulo Mineiro, 38025-180 Uberaba, MG, Brazil
2Human Immunology Research and Education Group-GEPIH, Technical Health School, Federal University of Paraíba, 58051-900 João Pessoa, PB, Brazil
3Laboratory of Parasitology Mycology, INSERM U399, Faculty of Medicine, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05, France
4Infectious Diseases Division, Federal University of Triângulo Mineiro, 38025-180 Uberaba, MG, Brazil

Received 6 November 2014; Revised 29 December 2014; Accepted 31 December 2014

Academic Editor: Oguz Kul

Copyright © 2015 Lucio Roberto Castellano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. W. Ghalib, M. R. Piuvezam, Y. A. W. Skeiky et al., “Interleukin 10 production correlates with pathology in human Leishmania donovani infections,” Journal of Clinical Investigation, vol. 92, no. 1, pp. 324–329, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Bourreau, C. Ronet, E. Darcissac et al., “Intralesional regulatory T-Cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis,” Infection and Immunity, vol. 77, no. 4, pp. 1465–1474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. P. Campanelli, A. M. Roselino, K. A. Cavassani et al., “CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells,” Journal of Infectious Diseases, vol. 193, no. 9, pp. 1313–1322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. L. R. Castellano, D. C. Filho, L. Argiro et al., “Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-γ production,” Human Immunology, vol. 70, no. 6, pp. 383–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. N. Rocha, R. P. Almeida, O. Bacellar et al., “Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis,” Journal of Infectious Diseases, vol. 180, no. 5, pp. 1731–1734, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Salhi, V. Rodrigues Jr., F. Santoro et al., “Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis,” Journal of Immunology, vol. 180, no. 9, pp. 6139–6148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. O'Garra, F. J. Barrat, A. G. Castro, A. Vicari, and C. Hawrylowicz, “Strategies for use of IL-10 or its antagonists in human disease,” Immunological Reviews, vol. 223, no. 1, pp. 114–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Bourreau, C. Ronet, P. Couppié, D. Sainte-Marie, F. Tacchini-Cottier, and P. Launois, “IL-10 producing CD8+ T cells in human infection with Leishmania guyanensis,” Microbes and Infection, vol. 9, no. 8, pp. 1034–1041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Gautam, R. Kumar, R. Maurya et al., “IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis,” Journal of Infectious Diseases, vol. 204, no. 7, pp. 1134–1137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. D. S. Santos, V. Boaventura, C. Ribeiro Cardoso et al., “CD8+ granzyme B+-mediated tissue injury vs. CD4+ IFNγ+ -mediated parasite killing in human cutaneous leishmaniasis,” Journal of Investigative Dermatology, vol. 133, no. 6, pp. 1533–1540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. F. O. Novais, L. P. Carvalho, J. W. Graff et al., “Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis,” PLoS Pathogens, vol. 9, no. 7, Article ID e1003504, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Cabrera, M.-A. Shaw, C. Sharples et al., “Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis,” Journal of Experimental Medicine, vol. 182, no. 5, pp. 1259–1264, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Bacellar, H. Lessa, A. Schriefer et al., “Up-regulation of Th1-type responses in mucosal leishmaniasis patients,” Infection and Immunity, vol. 70, no. 12, pp. 6734–6740, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. W. N. Oliveira, L. E. Ribeiro, A. Schrieffer, P. Machado, E. M. Carvalho, and O. Bacellar, “The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis,” Cytokine, vol. 66, no. 2, pp. 127–132, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Faria, K. J. Gollob, J. Barbosa Jr. et al., “Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis,” Infection and Immunity, vol. 73, no. 12, pp. 7853–7859, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Carvalho, W. D. Johnson, E. Barreto et al., “Cell mediated immunity in American cutaneous and mucosal leishmaniasis,” Journal of Immunology, vol. 135, no. 6, pp. 4144–4148, 1985. View at Google Scholar · View at Scopus
  17. R. Badaro, E. Falcoff, F. S. Badaro et al., “Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma,” The New England Journal of Medicine, vol. 322, no. 1, pp. 16–21, 1990. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sundar, F. Rosenkaimer, M. L. Lesser, and H. W. Murray, “Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis,” Journal of Infectious Diseases, vol. 171, no. 4, pp. 992–996, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. O. P. Singh and S. Sundar, “Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects,” Frontiers in Immunology, vol. 5, article 296, 2014. View at Publisher · View at Google Scholar
  20. W. Mayrink, A. C. de Carvalho Botelho, P. A. Magalhães et al., “Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 39, no. 1, pp. 14–21, 2006. View at Publisher · View at Google Scholar · View at Scopus